Who is Pfizer's biggest competitor?
Asked by: Adell Schulist | Last update: February 1, 2026Score: 4.9/5 (11 votes)
Pfizer's biggest competitors are global pharmaceutical giants like Johnson & Johnson, Merck & Co., Roche, AstraZeneca, and AbbVie, who compete across various therapeutic areas like oncology, immunology, and vaccines, with companies like Eli Lilly and Novo Nordisk also rising fast in specific markets like diabetes/obesity. While Johnson & Johnson often ranks highest in overall revenue, Pfizer frequently leads in pharma sales, but the competition is fierce, with players like AstraZeneca and Eli Lilly showing strong growth.
Who are the big 3 in pharma?
The three biggest pharmaceutical companies by market capitalization in early 2026 are generally considered Eli Lilly, Johnson & Johnson (J&J), and AbbVie, though rankings fluctuate, with some reports placing Eli Lilly at the top, followed by J&J and AbbVie or sometimes Novo Nordisk depending on the exact date and metric (market cap vs. revenue). Other giants consistently in the top tier include Merck, AstraZeneca, and Pfizer.
What is the top 5 pharmaceutical company in the world?
Eli Lilly is the largest pharma company in the world, with a market cap of $934.79 billion. Eli Lilly is followed by Johnson & Johnson ($488.74 billion), AbbVie ($388.43 billion), AstraZeneca ($281.86 billion), and Merck ($268.56 billion).
Does Warren Buffett own Pfizer?
No, Warren Buffett's Berkshire Hathaway does not currently own Pfizer (PFE) stock; they bought a small position in late 2020 but completely sold all their shares by the end of that year, exiting the investment quickly. While Buffett showed interest in the pharmaceutical sector during the pandemic, his firm sold off its Pfizer stake and other pharma stocks (like AbbVie, Merck, Bristol-Myers Squibb) in early 2021, indicating a shift away from the sector.
Is Merck bigger than Pfizer?
As of early 2026 data, Pfizer is generally larger than Merck in terms of sales, often holding the top spot globally for pharmaceutical revenue, though Merck & Co. (MSD) is also a dominant player, frequently ranking second or third, with some reports showing it slightly ahead of J&J and behind Pfizer for fiscal year 2024 revenue. However, when considering market capitalization in early 2026, Merck is often ranked higher than Pfizer, highlighting different aspects of company size, with Eli Lilly leading overall, say AlphaSense.
Pfizer CEO touts ‘most complete portfolio’ after $10B obesity drug win
Does Warren Buffett own Merck?
No, Warren Buffett's Berkshire Hathaway no longer owns Merck (MRK); they fully exited their stake in Merck & Co. (MRK) in the third quarter of 2021, after initially investing heavily in late 2020 and then gradually selling off shares. Berkshire had built a significant position in Merck in 2020 but sold all their shares by late 2021, missing out on subsequent price increases.
Who is the king of pharma?
Dilip Shanghvi. This is the latest accepted revision, reviewed on 17 January 2026. Dilip Shanghvi (born 1 October 1955) is an Indian billionaire businessman. Shanghvi is the founder of Sun Pharmaceuticals, a pharmaceutical company.
How risky is Pfizer stock?
What Could Cause The Stock To Decline? Patent Cliff Risk: Pfizer is confronted with a substantial “LOE wave” (Loss of Exclusivity) with $17-$18 billion in annual revenues at risk by 2028 from medications like Xeljanz, Prevnar, Eliquis, and Ibrance, as crucial patents expire between 2026 and 2028.
What is the 70/30 rule Buffett?
The "Buffett Rule 70/30" usually refers to an investment guideline suggesting 70% of a portfolio in growth assets (stocks) and 30% in safer assets (bonds or fixed income) for long-term balance, though some interpret it as 70% stocks and 30% "corporate workouts" (special situations), and Buffett also champions a 90/10 index fund strategy for most people. It's a flexible rule of thumb, not a rigid law, often adjusted by age, risk tolerance, and investment goals, with younger investors potentially favoring more stocks and those near retirement less.
Who owns the most stock in Pfizer?
The largest shareholder of Pfizer is The Vanguard Group, Inc., followed by BlackRock, Inc., and State Street Corporation, with these large institutional investors holding significant portions, around 9-10% for Vanguard and 8-9% for BlackRock, making Pfizer heavily institutionally owned.
Who is the richest pharma?
Ranked: The Top 50 Pharmaceutical Giants
With a market cap of over $578 billion, American pharmaceutical company Eli Lilly is the world's most valuable, known for diabetes medications and its newly-launched weight-loss drug. The average price of insulin in the U.S. is more than five times higher than other countries.
What are Pfizer's top selling drugs?
Pfizer's top-selling drugs recently include Eliquis (blood thinner), the Prevnar family (vaccines), Paxlovid (COVID-19 treatment), Vyndaqel (heart disease), Comirnaty (COVID-19 vaccine), and Ibrance (breast cancer), with revenues shifting significantly due to COVID-19 products like Paxlovid and Comirnaty, though Eliquis and Prevnar consistently rank high, according to Pfizer's 2024 annual report and Wikipedia.
What is the oldest pharmaceutical company in the world?
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed company.
Who is the highest paid CEO in pharma?
BioNTech's Uğur Şahin took the No. 1 spot on Fierce Pharma's list of the highest-paid pharma CEOs in 2024, raking in an industry-leading $287 million — mostly from exercising stock options granted in 2019. He far outpaced No. 2 David Ricks of Eli Lilly ($29.2M) and No.
Which country is no. 1 in pharma?
The United States is the #1 country in the pharmaceutical industry, leading significantly in market size, revenue (nearly half of the global market), drug development, and innovation, home to major players like Pfizer, J&J, and Merck. While China, Germany, Japan, and Switzerland are major players, the U.S. dominates due to its large market, fewer price controls, and strong R&D base.
Which are the best pharma stocks to buy?
Top pharma stocks to consider include growth leaders like Eli Lilly (LLY) and Novo Nordisk (NVO), defensive giants such as Johnson & Johnson (JNJ), and value/income plays like Merck (MRK), AbbVie (ABBV), Pfizer (PFE), and Bristol Myers Squibb (BMY), often praised for innovation in areas like weight loss drugs or strong cash flow, alongside established names like Amgen (AMGN) and Gilead (GILD), though the best choice depends on your investment goals (growth, income, value).
How long will $500,000 last using the 4% rule?
Your $500,000 can give you about $20,000 each year using the 4% rule, and it could last over 30 years. The Bureau of Labor Statistics shows retirees spend around $54,000 yearly. Smart investments can make your savings last longer.
What if you invested $1,000 in Berkshire Hathaway 10 years ago?
If you invested $1,000 in Berkshire Hathaway B shares (BRK.B) about 10 years ago (around late 2015/early 2016), your investment would have grown significantly, potentially reaching over $3,000 to $3,800 by late 2025, depending on the exact date, representing a gain of roughly 200-280% (excluding dividends) and outperforming the S&P 500 over that period, showcasing strong long-term value, according to analyses from sources like Zacks Investment Research, CNBC, and The Motley Fool.
What is Warren Buffett's #1 rule?
Warren Buffett's #1 rule of investing is famously simple and stark: "Rule No. 1: Never lose money. Rule No. 2: Never forget Rule No. 1.". This principle emphasizes capital preservation and avoiding significant losses, suggesting that protecting your principal is more crucial for long-term wealth building than chasing high, risky returns. It means focusing on buying good businesses at fair prices, understanding what you invest in, and being disciplined to prevent large, permanent losses, even if it means missing out on some fast gains.
What does Jim Cramer say about Pfizer stock?
During the lightning round, a caller sought Cramer's opinion on the stock, and he said: “Okay, Pfizer, really good yield, not a lot of momentum. Didn't like the update yesterday. I'm going to say just weak hold.”
Which stock is going to skyrocket in 2025?
Predicting a single "booming" stock for 2025 (which has already passed) is impossible, but strong performers and key sectors in 2025 included Nvidia (NVDA), AMD (AMD), and other tech giants like Microsoft (MSFT), Apple (AAPL), Amazon (AMZN), and Alphabet (GOOG), driven by AI, with specific growth opportunities also seen in healthcare (Eli Lilly, J&J), renewable energy (NextEra Energy, GE Vernova), and value tech (Yiren Digital). The overall trend favored growth stocks, though market volatility persisted.
Who is India's no. 1 billionaire?
Mukesh Ambani, leads as the 1st in India, with $103.96B in Diversified sector. Followed by Gautam Adani, 2nd in India, making waves in Diversified at 29th globally, and Savitri Jindal & family, 3rd in India, contributing significantly to Metals & Mining at 55th globally.
Who owns Cipla now?
As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. SBI Mutual Fund, LIC etc.
What is the pharma capital of the world?
India is the country with the highest number of pharmaceutical manufacturing facilities that are US-FDA certified, which is important for boosting its pharmaceutical export efforts.